Intangibles, Net

9 Months Ended

Sep. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles, NetIntangibles, net, consisted of the following:


	September 30, 2021
(in thousands)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	Straight-Line	$	13,540	$	(11,372)	$	2,168
Customer relationships	Accelerated	96,923		(94,461)		2,462
Currently marketed products	Straight-Line	275,700		(17,275)		258,425
Licenses	Straight-Line	85,800		(9,668)		76,132
Developed technology	Straight-Line	2,400		(344)		2,056
IPR&D	N/A	15,640		—		15,640
Total		$	490,003	$	(133,120)	$	356,883


	December 31, 2020
(in thousands)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	Straight-Line	$	13,540	$	(10,958)	$	2,582
Customer relationships	Accelerated	96,865		(93,770)		3,095
Currently marketed product	Straight-Line	142,900		(5,053)		137,847
Licenses	Straight-Line	85,800		(4,008)		81,792
Developed technology	Straight-Line	2,400		(144)		2,256
IPR&D	N/A	148,440		—		148,440
Total		$	489,945	$	(113,933)	$	376,012

The Company recorded amortization expense for its intangible assets of $8.4 million and $4.8 million for the three months ended September 30, 2021 and 2020, respectively, and $19.1 million and $6.1 million for the nine months ended September 30, 2021 and 2020, respectively.

In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:


(in thousands)	Amount
Remainder of 2021	$	8,370
2022	33,233
2023	32,634
2024	32,563
2025	32,508
2026 and thereafter	201,935
Total	$	341,243